PRODA BIOTECH LLC has a total of 16 patent applications. Its first patent ever was published in 2013. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ALEXION PHARMA INC, VEGENICS LTD and GILEAD BIOLOGICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | China | 3 | |
#4 | Australia | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials | |
#5 | Enzymes | |
#6 | Climate change adaptation technologies | |
#7 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Liu Zhi-Ren | 14 |
#2 | Zhang Yinwei | 9 |
#3 | Li Liangeiwei | 7 |
#4 | Wang Haizhen | 4 |
#5 | Li Liangwie | 1 |
#6 | Liu Zhi Ren | 1 |
#7 | Li Liamgwei | 1 |
#8 | Liu Zhiren | 1 |
Publication | Filing date | Title |
---|---|---|
CN107318262A | Destroy pyruvate kinase M2 and the molecule and its purposes of integrin interaction | |
CN106456696A | Therapeutic proteins for treating cancers and methods for using such proteins | |
CN104507970A | Method to prevent cancer metastasis and inhibit inflammation by inhibition of P68 interaction with calmodulin | |
WO2013123193A1 | Pyruvate kinase m2 neutralizing antibodies for inhibiting angiogenesis |